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ABSTRACT 
Immune responses to Epstein Barr virus (EBV) infection synergize with the main 
genetic risk factor HLA-DRB1*15:01 (HLA-DR15) to increase the likelihood to 
develop the autoimmune disease multiple sclerosis (MS) at least seven-fold. In order to 
gain insights into this synergy, we investigated HLA-DR15 positive human immune 
compartments after reconstitution in immune compromised mice (humanized mice) 
with and without EBV infection.  
We detected elevated activation of both CD4+ and CD8+ T cells in HLA-DR15 
donor-reconstituted humanized mice at steady state, even when compared to immune 
compartments carrying HLA-DRB1*04:01 (HLA-DR4), which is associated with other 
autoimmune diseases. Increased CD8+ T cell expansion and activation was also 
observed in HLA-DR15 donor-reconstituted humanized mice after EBV infection. 
Despite this higher immune activation, EBV viral loads were less well controlled in the 
context of HLA-DR15. Indeed, HLA-DR15-restricted CD4+ T cell clones recognized 
EBV-transformed B cell lines less efficiently and demonstrated cross-reactivity 
towards allogeneic target cells and one MS autoantigen. 
These findings suggest that EBV as one of the main environmental risk factors 
and HLA-DR15 as the main genetic risk factor for MS synergize by priming 
hyperreactive T cell compartments, which then control the viral infection less 
efficiently and contain cross-reactive CD4+ T cell clones. 
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INTRODUCTION 
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central 
nervous system (CNS) that often leads to substantial decline of sensory, motor, 
autonomic and neurocognitive functions. While considered to be an autoimmune, CD4+ 
T cell-mediated disorder, its etiology still remains poorly understood [1].  
Genome-wide association studies have identified the human leukocyte antigen 
(HLA) allele HLA-DRB1*15:01 (HLA-DR15) as the strongest associated genetic risk 
factor for MS. Other identified loci represent mainly immunologically relevant genes, 
particularly suggesting a role for helper T cell differentiation and function in MS 
pathogenesis [2, 3]. 
As the genetic background confers only partial risk for the disease, the role for 
environmental risk factors and their synergies with MS genetics have become 
increasingly apparent, especially in the first two decades of life [4]. Altered immune 
response to the Epstein Barr virus (EBV), including immunopathology during the acute 
primary EBV infection, called infectious mononucleosis (IM), is associated with MS 
and synergizes with HLA-DR15 resulting in a seven-fold increased risk of the disease 
[5]. The mechanisms behind this synergy remain unclear.   
EBV is a ubiquitous γ-herpesvirus infecting around 95% of the world adult 
population [6]. Following oral transmission, it starts a latent, growth transforming 
infection of B cells and persists in their memory compartment [7]. EBV is generally 
acquired early in childhood and leads to an asymptomatic primary infection at young 
age. However, if acquired in adolescence or early adulthood, it can manifest as IM [6], 
an acute illness sparking a vigorous immune response, characterized mainly by 
immensely expanded EBV-specific CD8+ T cells [8, 9]. Immunopathogenic and 
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exaggerated T cell responses are likely involved in IM being a phenomenon largely of 
late primary infection [10, 11].  
Viral and infectious agents have since a long time been thought to play a role in 
MS [12, 13]. Importantly, two studies demonstrated near-complete EBV seropositivity 
in pediatric MS patients [14, 15]. In addition, adult MS patients all became EBV 
positive prior to disease onset, suggesting that MS risk is extremely low in EBV 
seronegative individuals, but increases sharply after EBV infection [16] and even 
further after IM [17, 18]. Indeed, higher anti-EBV antibody titers before MS onset [19] 
are associated with disease risk [20]. The genetic risk for elevated anti-EBV nuclear 
antigen 1 (EBNA1) IgG titers also correlates with MS development [21] and the risk 
markedly increases in HLA-DRB1*15:01 positive individuals [22].  
However, adequate models are missing to study these interactions. Using a 
humanized mouse model (huNSG) of EBV infection, we investigated the role of HLA-
DR15 in the immune control of EBV. Using data accumulated in our laboratory over 
several years, we were able to stratify animals reconstituted with HLA-DR15 positive 
and negative donors. We have demonstrated that T cells from HLA-DR15 positive 
donors have higher basal activation levels. Despite enhanced T cell proliferation, EBV 
viral loads are elevated which suggests an impaired T cell-mediated immune control of 
EBV under the restriction of HLA-DR15. Importantly, we also find evidence for CD4+ 
T cell cross-reactivity to the MS autoantigen myelin basic protein (MBP), as well as 
increased alloreactivity in CD4+ T cell clones derived from HLA-DR15 individuals. 
Our data offers insights into the gene-environment interactions that could lead or add 
to the perturbed T cell homeostasis in MS. 
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RESULTS 
HLA-DR15+ donors reconstitute hyperactive T cells in huNSG animals  
We first wanted to investigate the effect of HLA-DR15 positive donors on T cell 
activation at steady state in humanized NOD-scid IL2 receptor γ-chain-deficient 
(huNSG) mice, as the major histocompatibility complex (MHC) Class II molecule 
HLA-DR15 carries the strongest genetic risk for multiple sclerosis [2]. To this end, we 
combined and stratified data from more than 3500 mice spanning six years of 
reconstitution experiments. This data was opportunistically pooled and was obtained 
by the same flow cytometry panel throughout (Fig. 1A, B, gating strategy is shown in 
Fig. S1, Fig. S2). Briefly, following intrahepatic injection of human fetal liver-derived 
human hematopoietic progenitor cells (i.e. donor) shortly after birth, animals were 
routinely bled after 3 months to check for the reconstitution of human immune system 
components in peripheral blood at steady state. Animals reconstituted with HLA-DR15 
positive donors demonstrated a higher activation of total T cells, CD4+ and CD8+ T 
cells when compared to animals reconstituted with HLA-DR15 negative donors (Fig. 
1A, Fig. S2A, B). This T cell activation was mainly observed among CD4+ T cells, 
which constitute around two thirds of the T cells after reconstitution. Furthermore, a 
higher activation frequency in the T cell compartment was also seen upon reconstitution 
with HLA-DR15 positive donors when compared with donors positive for HLA-DR4 
(Fig. 1B), an MHC Class II molecule implicated in other autoimmune diseases, 
including rheumatoid arthritis and type I diabetes [23, 24]. Interestingly, a difference 
in CD4+ T cell activation was not observed when HLA-DR4 positive versus negative 
donors (HLA-DR15 exclusive) were compared (Fig. S2C). These findings illustrate 
that HLA-DR15 hematopoietic progenitor cells reconstitute hyperactive T cells in the 
huNSG mouse model at steady state.  
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HLA-DR15 alters CD8+ T cell frequencies and activation during EBV infection of 
huNSG mice 
One of the hallmarks of IM is the vast expansion of CD8+ T cells, which are key to the 
immune control of EBV [25]. As the huNSG mouse model has been successfully used 
to study IM-like EBV infection [26], we examined the expansion of T cells following 
EBV infection in animals reconstituted with donors positive or negative for HLA-
DR15.  
During these experiments, animals were infected with a high dose (105 
infectious units) of the B95-8 strain of EBV and monitored for four to six weeks (Fig. 
2A). We first wanted to investigate T cell expansion following EBV infection at time 
of sacrifice (Fig. 2B to I). Even though EBV infection induces a large expansion of 
CD8+ T cells, we observed even higher frequencies (Fig. 2B, C) and total numbers (Fig. 
2D, E) in huNSG mice reconstituted with HLA-DR15 positive versus negative donors 
in both blood and spleen. While we did not observe a difference in the frequencies of 
CD4+ T cells (Fig. 2F, G) and total numbers in spleen (Fig. 2I), we did see higher total 
numbers of CD4+ T cells in the blood of HLA-DR15 reconstituted animals (Fig. 2H).  
In addition, there were higher numbers of activated CD8+ T cells (Fig. 3A, B) 
in blood and spleen of HLA-DR15 reconstituted animals, even though no differences 
were observed in the activation of the CD4+ T cell compartment (Fig. 3C, D). Similar 
results were also observed for total T cell frequencies, numbers and activation in blood 
and spleen (Fig. S3). These observations suggest a more robust, HLA-DR15-associated 
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Reduced EBV-specific immune control in HLA-DR15-reconstituted huNSG 
In our huNSG model of EBV infection (105 infectious particles), blood viral DNA loads 
are usually detectable at three weeks post infection [26]. Interestingly, we observed a 
higher EBV viral load at time of sacrifice in animals reconstituted with HLA-DR15 
positive versus HLA-DR15 negative donors (Fig. 4A) or HLA-DR4 positive donors 
(Fig. 4B), even though their initial reconstitution was similar (Fig. S4A, B). It has 
previously been shown that CD8+ T cell expansion and blood viral load are positively 
correlated with disease severity in IM patients [8]. Indeed, we observed positive 
correlations between EBV viral loads in the blood and frequencies of activated CD8+ 
T cells in the blood (Fig. 4C), as well as EBV viral loads in the spleen and frequencies 
of activated CD8+ T cells in the spleen (Fig. 4D). Similar correlations of EBV viral 
loads with total numbers of activated CD8+ T cells were also observed in blood and 
spleen (Fig. S4C, D). This data, together with increased frequencies (Fig. 2B to E) and 
activation (Fig. 3A, B) of CD8+ T cells, suggests a reduced EBV-specific immune 
control despite significant CD8+ T cell expansion that is associated with HLA-DR15.  
The humoral immune response has been challenging to study in the huNSG and 
other humanized mouse models. These animals lack normal lymph node development 
and have poor germinal center organization, thereby hampering B cell class switching 
and affinity maturation [26]. Upon measuring serum anti-EBV nuclear antigen 1 
(EBNA1) immunoglobulin M (IgM), we were, however, able to find a fraction of EBV-
infected animals positive for these antibodies (Fig. 4E). The humoral anti-EBNA1 IgM 
titer from animals with a humoral response above threshold correlated with blood EBV 
viral loads (Fig. 4F), however due to the infrequent IgM responses, we were not able to 
compare between HLA-DR15 positive and negative animals. Thus, EBV is less well 
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immune controlled in the context of HLA-DR15; higher viral loads were observed 
despite elevated CD8+ T cell expansion. 
 
Myelin antigen recognition, alloreactivity and lower specificity by HLA-DR15-
restricted T cells 
EBNA1-specific CD4+ T cells have been previously shown to cross-react to myelin 
antigens [27]. We were therefore interested in examining if CD4+ T cells isolated from 
EBV-infected animals would cross-react to peptide pools spanning myelin basic protein 
(MBP) and myelin oligodendrocyte glycoprotein (MOG). These two myelin-derived 
MS autoantigens have been previously studied for their immunodominance in humans 
and/or encephalitogenic potential in animal models (reviewed in [28, 29]) and show 
comparable mathematically-predicted epitope binding affinity to HLA-DR15 and 
HLA-DR4 molecules [30]. Furthermore, immunodominant high avidity target peptides 
of MBP are known to be recognized in the context of both HLA-DR15 and HLA-DR4 
[30, 31]. CD4+ T cells from the splenocytes of EBV-infected animals were expanded 
before being stimulated with MBP, MOG or EBV peptide pools. Frequency of IFNγ-
producing cells was then measured in the ELISpot assay. Interestingly, we observed 
that CD4+ T cells from nearly all HLA-DR15 and from a fraction of HLA-DR4 
reconstituted animals produced IFNγ in response to MBP stimulation (Fig. 5A, Fig. 
S5A). EBV derived peptide reactivity was more pronounced in a subset of HLA-DR4 
reconstituted animals. These findings suggest MBP recognition by HLA-DR15 positive 
CD4+ T cells of EBV infected humanized mice. 
Considering the essential role of T cells in the immune control of EBV infection 
[25] and our results suggesting that EBV might be less well controlled under HLA-
DR15 restriction, we examined EBV infected B cell recognition of individual CD4+ T 
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cell clones. For this purpose, CD4+ T cell clones were isolated from EBV-infected, 
HLA-DR15 or HLA-DR4 reconstituted animals using bare lymphocyte syndrome 
lymphoblastoid cell lines (BLCLs; cells isolated from bare lymphocyte syndrome 
patients lacking MHC Class II expression) transfected with single MHC Class II 
molecules as targets. CD4+ T cells that produced IFN in response to either HLA-
DR15+ or HLA-DR4+ BLCLs were cloned (Fig. 5B). During the initial T cell clone 
screening for IFNγ production via ELISA, we observed BLCL-restricted IFNγ 
production in only 27% of HLA-DR15-restricted T cell clones, versus in 71% of HLA-
DR4-restricted T cell clones tested (data not shown). Three HLA-DR15-restricted and 
two HLA-DR4-restricted CD4+ T cell clones were used in the assays.  
The CD4+ T cell clones were incubated together with their HLA matched (auto) 
or mismatched (allo) BLCLs as targets (HLA-DR15-expressing or HLA-DR4-
expressing, depending on the genetic restriction of the T cell clone). Intracellular 
cytokine staining for IFNγ (Fig. 5C), TNFα (Fig. 5D) and IL-2 (Fig. 5E) revealed 
stronger alloreactive responses from CD4+ T cell clones restricted by HLA-DR15. In 
trying to isolate the specificity of the responses that we observed, the responses towards 
HLA mismatched BLCLs were subtracted from the recognition of HLA matched 
targets (Fig. 5C to E, lower panels). In contrast, expression of the transcription factors 
T-bet and EOMES by the investigated T cell clones was not largely altered by the 
different stimulations (Fig. S5C, D). 
To test their cytotoxic ability, the CD4+ T cell clones were also incubated 
together with their HLA matched or mismatched BLCLs as targets. While at 6 hours of 
incubation (Fig. 6A), the pattern is less evident, at 18 hours of incubation (Fig. 8B), 
HLA-DR4-restricted CD4+ T cell clones killed their targets with higher specificity as 
HLA-DR15-restricted CD4+ T cell clones showed higher alloreactive responses. In 
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addition, degranulation assessed by CD107a surface expression and the cytotoxic 
granule marker granzyme B were used to gain insight into the cytolytic potential of the 
T cell clones. Interestingly, HLA-DR4-restricted CD4+ T cell clones degranulated very 
specifically, whilst HLA-DR15-restricted CD4+ T cell clones not only degranulated 
less, but also demonstrated significant degranulation to the allogeneic target (Fig. 6C). 
HLA-DR15-restricted clones also displayed high granzyme B expression when 
incubated with both HLA matched and mismatched targets, whilst HLA-DR4-restricted 
clones seemed to up-regulate granzyme B only upon recognition of the HLA matched 
target (Fig. 6D). This is also evident when responses towards HLA mismatched BLCLs 
were subtracted from the recognition of HLA matched targets (Fig. 6A to D, lower 
panels) and further highlight above-mentioned results.  
These data provide evidence for CD4+ T cell cross-reactivity to myelin antigens. 
In addition, weaker HLA-DR15-restricted CD4+ T cell responses against EBV-
transformed B cells, but also inflammatory responses that show tendencies towards 
alloreactivity. Thus, the HLA-DR15 genetic risk factor may stimulate EBV-specific 
CD4+ T cell responses that recognize allogeneic target cells as well as myelin antigens, 
and that provide insufficient help to CD8+ T cells in order to efficiently control EBV 
infection. This could lead to both IM-like lymphocytosis and promote cross-reactive 
autoimmune CD4+ T cell stimulation.  
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DISCUSSION 
Evidence suggests dysregulated adaptive immunity to be at the core of MS [1]. HLA 
class II molecules, such as HLA-DR15, are expressed on antigen presenting cells. They 
present peptides derived from self or exogenous proteins to CD4+ T cells, which then 
support and strengthen cellular and humoral immune responses [32]. Indeed, in addition 
to the importance of CD4+ T cells in MS pathogenesis, evidence from CNS-infiltrating 
immune cells in patients and B cell-depleting therapies suggests additional roles for 
CD8+ T cells and B cells in the disease [33, 34], supported by or supporting autoimmune 
CD4+ T cell responses. 
In vivo EBV infection of huNSG mice has allowed us to study the interaction 
between the main genetic risk factor for MS, HLA-DR15, with the main environmental 
risk factor, EBV-induced immune responses [4]. Similar to MS patients, we observed 
elevated EBV induced T cell responses in huNSG mice with HLA-DR15 positive 
immune compartments [27, 35]. These seemed to result from a higher constitutive T 
cell activation and increased CD8+ T cell expansion due to less well controlled viral 
loads in connection with this particular MHC class II molecule. Furthermore, we 
observed CD4+ T cell cross-reactivity to the MS autoantigen MBP and CD4+ T cell 
clones isolated from these EBV-infected huNSG mice that were selected for HLA-
DR15-restricted EBV transformed B cell (LCL) recognition displayed diminished 
immune recognition of EBV-infected B cells and higher cross-reactivity to HLA-DR 
mismatched targets. These findings point to both diminished immune control of EBV 
and its proinflammatory effects, as well as increased cross-reactivity of the CD4+ T cell 
compartment that is more activated by the poorly controlled EBV infection in the 
context of HLA-DR15. In this way, EBV-induced immune responses could synergize 
with HLA-DR15 to enhance MS.  
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Indeed, cross-reactivity with molecular mimicry between EBV and myelin-
derived autoantigens has been proposed previously. Primarily, EBNA1 and lytic EBV 
antigen-specific antibodies, in addition to CD4+ T cell responses, are elevated in 
patients with MS and sometimes enriched in the CNS [19, 27, 35-39]. Some of these 
have indeed been suggested to cross-react with CNS autoantigens, like myelin basic 
protein, heterogeneous nuclear ribonucleoprotein L, septin-9 or anoctamin 2  [27, 39-
42]. This cross-reactivity could amplify T cell and antibody responses against select 
EBV gene products, including EBNA1, BFRF3 and BRRF2 [27, 39, 41], as well as lead 
to the local restimulation in the CNS to promote MS-associated lesion formation. 
Moreover, EBV might induce homing capacities in the respective cross-reactive 
lymphocyte populations to guide them to the CNS. In line with this, the chemokine 
CXCL10 was shown to be expressed by EBV-transformed cells, attracting EBV-
specific T cells [43] and was also found in the CSF of MS patients [44].  
Both B and T cell homing of cross-reactive specificities would however be a 
prerequisite of focusing the resulting autoimmunity on the CNS. Along these lines the 
α41 integrin has been found to be essential for CNS homing of T cells [45]. In 
addition, the chemokine receptors CXCR3, CCR5, CCR6 and CCR7 have been 
implicated in brain infiltration of T cells [44, 46, 47] and should be investigated for 
presence of cross-reactive lymphocyte populations. Cross-reactive T and B cells might 
then re-stimulate each other in the CNS of patients with MS to promote relapsing-
remitting and progressive courses of the disease.  
Such T cell stimulatory capacity of B cells in MS brains could be further 
augmented by EBV infection that increases co-stimulatory activity for T cell 
stimulation [48]. Along these lines, EBV-infected B cells have been detected in the 
meninges and lesions in the brains of MS patients [49], but these findings are heavily 
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debated [50]. Considering EBV biology and life cycle, B cell stimulation of T cell 
responses in secondary lymphoid organs might be of great importance. As already 
mentioned, EBV establishes a life-long infection in memory B cells and by doing so, 
modulates their differentiation and function, and promotes their survival [51]. Indeed, 
memory B cells have recently been shown to mediate the activation of autoreactive 
CD4+ T cells [52]. It is plausible that EBV infects autoreactive B cells, or B cells that 
might present antigen to pathogenic, cross-reactive T cells over a long period of time. 
In addition, in genetically susceptible hosts, acute immune pathologies like IM could 
serve to decrease the threshold of T cell activation, facilitating pathogenic B-T cell 
interactions. The exaggerated EBV-specific T cell expansion during IM could expand 
T cells that have been selected in the thymus by self-peptides and will only undergo 
full activation under acute EBV infection to remain as memory T cells. 
Indeed, B cell depleting therapies, which leave oligoclonal antibody production 
in the CNS and systemic antibody production by long-lived plasma cells in the bone 
marrow usually unaffected, have demonstrated beneficial effects in MS patients [34, 
53]. Furthermore, adoptive transfer of EBV-specific in vitro-expanded T cell lines into 
patients with MS, even at advanced disease, has demonstrated some encouraging results 
[54]. These T cells might eliminate an EBV-infected B cell compartment that stimulates 
autoreactive T cell responses, possibly even in the brain. Thus, inefficient immune 
control of EBV-infected B cells in the context of HLA-DR15 might allow for both 
priming of cross-reactive T cell responses and their local restimulation by EBV-




Zdimerova et al., HLA-DR15 restricted immune control of EBV 15 
MATERIALS & METHODS 
Animal work  
NOD-scid IL2 receptor γ-chain-deficient (NSG) animals with or without an HLA-A2 
(NSG-A2) heavy chain transgene (Jackson Laboratory, Bar Harbor, Maine, USA) were 
maintained under specific pathogen-free conditions at the Institute of Experimental 
Immunology, University of Zürich, Switzerland. Newborn pups (1-5 days old) were 
sublethally irradiated with 1Gy and 5 to 7 hours later, intrahepatically injected with 
around 1.5-3 x 105 human fetal liver (Advanced Bioscience Resources)-derived and 
HLA typed CD34+ hematopoietic progenitor cells. CD34+ cells were isolated by 
magnetic bead separation based on manufacturer’s instructions (Miltenyi Biotech) and 
frozen in liquid nitrogen. After twelve weeks, peripheral blood was collected from the 
tail vein and analyzed for human CD45+, CD3+, CD4+, CD8+ and HLA-DR+ cells by 
flow cytometry. Both female and male animals 3 to 5 months old and engrafted with 
human immune cells were intraperitoneally injected with 105 EBV Raji infectious units 
(RIU) or PBS and monitored for up to 6 weeks. Animals used in each experiment were 
reconstituted from a single donor. NSG-A2 animals were transplanted with HLA-A2 
positive CD34+ cells.  
 
EBV 
EBV strain B95-8 was produced in human embryonic kidney HEK293 cells (ATCC) 
containing a GFP-encoding wild type EBV BACmid (p2089; kind gift from H.-J. 
Delecluse) [55]. Virus concentrates were titrated on Raji cells (ATCC) and GFP-
expressing cells were analysed two days later by flow cytometry (FACSCanto II or 
LSR Fortessa, BD Biosciences) to determine the EBV RIU. 
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Enzyme-linked Immunosorbent assay (ELISA) 
IFN in T cell clone supernatants was measured by the human IFN ELISA 
development kit (Mabtech AB) according to the manufacturer’s instructions. EBNA1 
IgM in huNSG mouse serum was measured by the Epstein-Barr virus EBNA1 IgM 
ELISA (IBL International) following the manufacturer’s instructions. The threshold to 
determine positive IgM values was set by the mean + 2x standard deviation of PBS 
animals.  
 
Enzyme-linked Immunospot assay (ELISpot) 
CD4+ T cells were isolated from the splenocytes of HLA-DR15 or HLA-DR4 
reconstituted, EBV-infected animals (negative magnetic bead separation, Miltenyi 
Biotec) and expanded by seeding on irradiated allogeneic LCLs as feeder cells (45Gy) 
with 1 g/ml PHA-L (Merck Millipore) and 20 U/ml IL-2 (Peprotech). Fresh IL-2 was 
added three times per week.  
 IFN-producing CD4+ T cells were assayed by the human IFNγ ELISpot BASIC 
kit (ALP) (Mabtech AB) according to the manufacturer’s instructions. On day 15 of 
expansion, CD4+ T cells were seeded on pre-coated 96 well plates (MultiScreen Filter 
Plates, Merck Millipore) at 2.7-5 x 104 per well with 2 x 104 HLA-matched BLCLs 
(HLA-DR15 or HLA-DR4-transfected). Myelin-basic protein (MBP), myelin 
oligodendrocyte glycoprotein (MOG) and EBV peptide pools (kind gift from R. Martin, 
unpublished) were added at 1 M concentration for each peptide in the pool (DMSO 
concentration <0.5%) and incubated with the cells for 28 hours at 37C. CD4+ T cells 
alone were used as negative control and CD4+ T cells stimulated with PMA/ionomycin 
as positive control. Wells were counted with the AID ELISpot reader and software 
(Autoimmun Diagnostika GmbH).  
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T cell cloning  
CD4+ T cells were isolated from the splenocytes of EBV-infected animals (magnetic 
bead separation, Miltenyi Biotec) and stimulated with transgenic HLA-matched bare 
lymphocyte syndrome lymphoblastoid cell lines (BLCLs; HLA-DR15 or HLA-DR4-
transfected) for 3-4 hours at 37C. IFN-producing cells were then selected with the 
IFN Secretion Assay – Detection kit (PE), human (Miltenyi Biotech) and diluted into 
96-well plates pre-filled with irradiated PBMC feeder cells and HLA matched BLCLs 
(20Gy and 60Gy, respectively). IL-2 (Peprotech) was added two days later and 
subsequently twice a week at 100-125 U/ml. Two to four weeks later, growing clones 
were screened with the Human IFN ELISA development kit (Mabtech AB) and IFN-
producing clones were placed into culture. CD4+ T cell clones were fed every two to 
three weeks with irradiated PBMC feeder cells and HLA matched BLCLs, together 
with 100-125 U/ml of IL-2.  
For T cell clone killing assays, BLCLs were labelled with PKH26 (Sigma-
Aldrich). CD4+ T cell clones were then incubated alone, or with labelled matched or 
mismatched BLCLs at 5:1 ratio for 6 or 18 hours. TO-PRO-3 dye (Life Technologies) 
was used as a dead cell indicator. For degranulation experiments, CD4+ T cell clones 
were incubated alone, or with matched or mismatched BLCLs at 1:1 ratio and stained 
for CD107a (BD Biosciences). Cells were incubated for 2 hours before the addition of 
Brefeldin A (Sigma-Aldrich) and incubated for further 6 hours. For transcription factor 
expression experiments, CD4+ T cell clones were incubated alone, or with matched or 
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Flow cytometry 
Whole blood was lysed with ACK lysing buffer (Gibco) and washed to obtain 
peripheral blood mononuclear cells (PBMCs). Spleens were physically dissociated 
through a 70 M strainer and layered on Ficoll-Paque (GE Healthcare) for the 
separation of mononuclear cells by density gradient centrifugation. Total numbers of 
leukocytes were calculated from the white blood cell count measured by Beckman 
Coulter AcT diff Analyzer. PBMCs, splenocytes or CD4+ T cell clones were stained 
with extracellular antibodies for 20 minutes at 4C, washed and resuspended either in 
PBS or fixed in 1% paraformaldehyde (PFA). For intracellular staining, extracellular-
stained samples were processed with the Cytofix/Cytoperm Fixation/Permeabilization 
Kit (BD Biosciences) according to manufacturer’s instructions. For intranuclear 
staining, extracellular-stained samples were processed with the Foxp3/Transcription 
Factor Staining Buffer Set (eBioscience, Thermo Fisher Scientific) following the 
manufacturer’s instructions. Live/dead Near IR (Invitrogen) or Zombie NIR 
(Biolegend) was used for live cell separation.  
 
Antibody clones used in this study: CD45 (HI30, Biolegend), CD3 (OKT3, UCHT1, 
Biolegend), CD4 (OKT4, RPA-T4, Biolegend), CD8 (SK1, Biolegend), CD19 (HIB19, 
Biolegend), HLA-DR (G46-6, BD Biosciences, L243, Biolegend), Eomes (WD1928, 
eBioscience), T-bet (4B10, eBioscience), IFN (4S.B3, eBioscience), IL-2 (MQ1-
17H12, eBioscience), TNF (Mab11, BD Biosciences), Granzyme B (GB11, BD 
Biosciences), CD107a (H4A3, BD Biosciences).  
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Samples were acquired on the FACSCanto II or LSR Fortessa (BD Biosciences) and 
analysed using the Flowjo Software (Becton, Dickinson & Company) following 
Cossarizza and colleagues [56] whenever possible.  
 
Viral load quantification  
Splenic tissue was processed for DNA isolation using the DNeasy Blood and Tissue 
Kit (QIAGEN) and total DNA from whole blood was extracted using the NucliSENS 
EasyMAG System (bioMérieux), following the manufacturer’s instructions. TaqMan 
real-time PCR (Applied Biosystems) was used to quantify EBV DNA, with modified 
primers for the BamH1 W fragment (5′-CTTCTCAGTCCAGCGCGTTT-3′ and 5′-
CAGTGGTCCCCCTCCCTAGA-3′) and a fluorogenic probe (5′-FAM 
CGTAAGCCAGACAGCAGCCAATTGTCAG-TAMRA-3′). All samples were 
analyzed in duplicates.  
 
HLA typing 
DNA was extracted using the QIAGEN GmbH reagent, according to the manufacturer’s 
instructions. Commercial HLA kits (Fujirebio Diagnostics Inc.) were used to identify 
the HLA alleles using a PCR sequence-specific oligonucleotide reverse assay. Data 




Statistical analysis was performed with the GraphPad Prism Software. The Mann-
Whitney U test was used to analyze unpaired data with a non-Gaussian distribution. 
Correlations on non-Gaussian distributed data were analyzed using the Spearman’s 
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rank correlation coefficient. The D’Agostino-Pearson omnibus normality test was used 
to determine normality of data. A p value < 0.05 was considered statistically significant.  
 
Ethics statement  
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and 2019-00837). 
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FIGURE LEGENDS 
Fig. 1: Higher T cell activation in HLA-DR15+ donor reconstituted huNSG mice. 
Three months post reconstitution, animals were bled and analyzed for reconstitution of 
human immune system components in peripheral blood. Data was stratified into 
animals reconstituted with HLA-DR15 negative (DR15-), HLA-DR15 positive (DR15+) 
(A) and HLA-DR4 positive (DR4+), HLA-DR15 positive (DR15+DR4-) (B) donors and 
collected by flow cytometry. T cell activation was analyzed by positive staining of 
HLA-DR (DR). Data shown are combined from > 96 donors (n of animals = 3579, 
CD4+ T cell activation n = 2991) (A) and 51 donors (n of animals = 1230, CD4+ T cell 
activation n = 1135) (B). * p < 0.05, *** p < 0.001, **** p < 0.0001, significant 
comparisons are indicated and significance is based on the Mann-Whitney U test. Each 
symbol indicates one animal (mean ± SEM). 
 
Fig. 2: EBV-infected HLA-DR15+ reconstituted mice have higher frequencies of 
CD8+ T cells. Schematic depiction of analysed EBV infection experiments. After 3-5 
months of human immune compartment reconstitution, animals were injected with 105 
EBV infectious units or PBS intraperitoneally and monitored for 4-6 weeks by visual 
examination, weight measurements and flow cytometry (A). At time of sacrifice (4-6 
weeks post infection), frequencies of CD8+ T cells in blood and spleen (B, C), total 
numbers of CD8+ T cells in blood and spleen (D, E), frequencies of CD4+ T cells in 
blood and spleen (F, G), and total numbers of CD4+ T cells in blood and spleen (H, I), 
respectively, were analysed and stratified into animals reconstituted with HLA-DR15 
negative (DR15-) and HLA-DR15 positive (DR15+) donors. Data shown are combined 
from 11 to 24 experiments and contain 19-65 animals per group. * p < 0.05, ** p < 
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0.01, significant comparisons are indicated and significance is based on the Mann-
Whitney U test. Each symbol indicates one animal (mean ± SEM).  
 
Fig. 3: EBV-infected HLA-DR15+ reconstituted mice have higher numbers of 
activated CD8+ T cells. As indicated, animals were injected with 105 EBV infectious 
units or PBS intraperitoneally. At time of sacrifice (4-6 weeks post infection), total 
numbers of activated CD8+ T cells (A, B) and activated CD4+ T cells (C, D) in blood 
and spleen, respectively, were analysed and stratified into animals reconstituted with 
HLA-DR15 negative (DR15-) and HLA-DR15 positive (DR15+) donors. T cell 
activation was analyzed by positive staining of HLA-DR by flow cytometry. Data 
shown are combined from 11 to 13 experiments and contain 19-32 animals per group. 
* p < 0.05, ** p < 0.01, significant comparisons are indicated and significance is based 
on the Mann-Whitney U test. Each symbol indicates one animal (mean ± SEM). 
 
Fig. 4: EBV viral loads in huNSG mice correlate with activated CD8+ T cells and 
humoral IgM responses and are higher in HLA-DR15+ reconstituted animals. 
Blood EBV viral loads at time of sacrifice (4-6 weeks post infection with 105 EBV 
infectious units) of animals reconstituted with HLA-DR15 positive (DR15+), HLA-
DR15 negative (DR15-) (n = 42 and 70, respectively) (A), HLA-DR15 positive DR4 
negative (DR15+DR4-) and HLA-DR4 positive (DR4+) (n = 38 and 22, respectively) 
(B) donors, measured by TaqMan real-time PCR. Red lines depict the median and 
significance is based on the Mann-Whitney U test (A, B). (C) Frequencies of activated 
CD8+ T cells in blood were plotted relative to blood EBV viral loads (n = 56). (D) 
Frequencies of activated CD8+ T cells in spleen were plotted relative to spleen EBV 
viral loads (n = 60). T cell activation was analyzed by positive staining of HLA-DR by 
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flow cytometry (C, D). (E) Animals were injected with 105 EBV infectious units or 
PBS intraperitoneally. At time of sacrifice, serum was collected and analysed for anti-
EBNA1 IgM antibodies via ELISA. Red lines depict the mean and dotted line 
represents threshold set at mean + 2x standard deviation of PBS animals (n PBS = 33, 
EBV = 71). (F) Levels of anti-EBNA1 IgM antibodies of animals above threshold were 
plotted relative to EBV viral loads in blood. Data shown are combined from 11 to 28 
experiments. * p < 0.05, *** p < 0.001, **** p < 0.0001, significant comparisons are 
indicated. All correlations were analyzed using the nonparametric Spearman 
correlation, which examines rank correlation. Each symbol indicates one animal. 
 
Fig. 5: HLA-DR15-restricted EBV-infected B cell-specific CD4+ T cell clones show 
cross-reactive cytokine production. Splenocyte-derived and expanded CD4+ T cells 
from HLA-DR15 (DR15) or HLA-DR4 (DR4) reconstituted animals stimulated by 
MBP, MOG or EBV peptides and analysed for IFNγ production via ELISpot assay (A). 
No peptide addition served as negative control (neg ctrl) and each point indicates one 
well. Animals from two experiments were used (eight in total, two per experiment and 
condition). Schematic depiction of T cell cloning (B). CD4+ T cell clones were cloned 
from EBV-infected animals using bare lymphocyte syndrome lymphoblastoid cell lines 
(BLCLs) transfected with single MHC Class II molecules as targets using the IFNγ 
capture assay. HLA-DR15 (DR15) or HLA-DR4 (DR4)-restricted CD4+ T cell clone 
functionality was examined through the production of the cytokines IFNγ (C), TNFα 
(D) and IL-2 (E) after 8 hours of incubation with allogeneic (allo) or autologous (auto) 
BLCL (HLA-DR15-expressing or HLA-DR4-expressing, depending on the genetic 
restriction of the T cell clone). To suggest the specificity of the response, allo values 
were additionally subtracted from auto values and included in bottom panels (C-E). 
Zdimerova et al., HLA-DR15 restricted immune control of EBV 31 
Three HLA-DR15-restricted and two HLA-DR4-restricted CD4+ T cell clones were 
used and data from 5 experiments are included. Each symbol represents one well and 
individual clones are indicated. Lines indicate mean ± SEM. ** p < 0.01, *** p < 0.001, 
**** p < 0.0001, significant comparisons are indicated and significance is based on the 
Mann-Whitney U test. 
 
Fig. 6: HLA-DR15-restricted EBV-infected B cell-specific CD4+ T cell clones 
demonstrate higher alloreactivity in cytotoxicity. CD4+ T cell clones were cloned 
from EBV-infected animals using BLCLs transfected with single MHC Class II 
molecules as targets. HLA-DR15 (DR15) or HLA-DR4 (DR4)-restricted CD4+ T cell 
clone responses are measured via target cell killing after 6 (A) and 18 hours (B), 
degranulation by marker CD107a surface upregulation after 8 hours (C) and granzyme 
B expression after 8 hours (D) in response to the allogeneic (allo) or autologous (auto) 
BLCL (HLA-DR15-expressing or HLA-DR4-expressing, depending on the genetic 
restriction of the T cell clone). Allo values were additionally subtracted from auto 
values and included in bottom panels (A-D). Three HLA-DR15-restricted and two 
HLA-DR4-restricted CD4+ T cell clones were used and data from 2 to 5 experiments 
are included. Each dot represents one well and individual clones are indicated. The 
mean ± SEM is depicted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, 
significant comparisons are indicated and significance is based on the Mann-Whitney 
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Attenuated immune control of Epstein Barr virus in humanized mice is associated with the 
multiple sclerosis risk factor HLA-DR15 
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Fig. 1: Gating strategy to determine reconstitution frequencies of human 
immune system compartments and their expression of the activation marker HLA-DR. Three 
months post reconstitution, animals were bled and analyzed for reconstitution of human immune 
system components in peripheral blood. Cells are first gated on lymphocytes, singlets, human 
CD45+ cells, B cells (CD19+) and T cells (CD3+). T cells are then further gated into CD4+ and 
CD8+ populations and T cell activation is analyzed by positive staining for HLA-DR.   
 
Supplementary Fig. 2: No difference in CD4+ T cell activation at steady state between HLA-
DR4+ and HLA-DR4- donors. Three months post reconstitution, animals were bled and analyzed 
for reconstitution of human immune system components in peripheral blood. Data is stratified into 
NSG (A) and NSG-A2 (B) animals reconstituted with HLA-DR15 negative (DR15-), HLA-DR15 
positive (DR15+) (A-B, D) HLA-DR4 positive (DR4+) and HLA-DR4 negative (DR4-) (C) donors. 
Data are pooled from both NSG and NSG-A2 animals (n of animals = 2064, CD4+ T cell activation 
n = 1915) exclusive of HLA-DR15+ donors (C). Reconstitution of B cells in DR15- and DR15+ 
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reconstituted animals. Data are pooled from both NSG and NSG-A2 animals (n of animals = 2905) 
(D). ** p < 0.01, *** p < 0.001, **** p < 0.0001, significant comparisons are indicated and 
significance is based on the Mann-Whitney U test. Each symbol indicates one animal (mean ± 
SEM).  
 
Supplementary Fig. 3: Higher total numbers and total activated T cells in EBV-infected 
huNSG animals. As indicated in Fig. 2A, animals were injected with 105 EBV infectious units or 
PBS intraperitoneally and monitored for 4-6 weeks. At time of sacrifice (4-6 weeks post infection), 
frequencies of total T cells in blood and spleen (A, B), total numbers of T cells in blood and spleen 
(C, D) and total numbers of activated T cells in blood and spleen (E, F), respectively, were 
analysed and stratified into animals reconstituted with HLA-DR15 negative (DR15-) and HLA-
DR15 positive (DR15+) donors. T cell activation was analyzed by positive staining of HLA-DR 
(E, F). Data shown are combined from 11 to 24 experiments and contain 19-65 animals per group. 
* p < 0.05, ** p < 0.01, significant comparisons are indicated and significance is based on the 
Mann-Whitney U test. Each symbol indicates one animal (mean ± SEM). 
 
Supplementary Fig. 4: Equivalent reconstitution in humanized mouse cohorts and activated 
CD8+ T cells correlate to EBV viral load. Frequencies of initial reconstitution of human CD45+ 
cells in humanized mouse cohorts, of which some animals were EBV infected (Fig. 4A, B). 
Reconstitution of HLA-DR15-, HLA-DR15+ reconstituted animals (A) and HLA-DR4+, HLA-
DR15+DR4- reconstituted animals (B) is shown. (A) In left column, 70/527 animals and in right 
column, 42/173 animals were used for EBV infection. (B) In left column, 22/159 animals and in 
right column, 38/145 animals were used for EBV infection. (C) Total numbers of activated CD8+ 
Zdimerova et al., HLA-DR15 restricted immune control of EBV 3 
 
 
T cells in blood were plotted relative to blood EBV viral loads (n = 52). (D) Total numbers of 
activated CD8+ T cells in spleen were plotted relative to spleen EBV viral loads (n = 56). T cell 
activation was analyzed by positive staining of HLA-DR (C, D). Data shown are combined from 
11 experiments. * p < 0.05, ** p < 0.01, **** p < 0.0001, significant comparisons are indicated. 
All correlations are analyzed using the nonparametric Spearman correlation, which examines rank 
correlation. Each symbol indicates one animal. 
 
Supplementary Fig. 5: MBP reactivity, activation, T-bet and EOMES expression by HLA-
DR15 or -DR4 positive CD4+ T cells of EBV infected humanized mice. Splenocyte-derived and 
expanded CD4+ T cells from HLA-DR15 (DR15) or HLA-DR4 (DR4) reconstituted animals 
stimulated by MBP peptides and analysed for IFNγ production via ELISpot assay (A). Negative 
controls (cells without peptide) were subtracted from data points and each point indicates one well. 
Individual animals from two experiments are shown and indicated by numbers. CD4+ T cell clones 
were cloned from EBV-infected animals using BLCLs transfected with single MHC Class II 
molecules as targets. CD4+ T cell clones were incubated for 8 hours alone (T only), with matched 
(auto) or mismatched (allo) BLCL. Their activation was analyzed by positive staining for HLA-
DR (B), T-bet (C) and EOMES (D) transcription factor expression are shown. Data shown are 
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